Match!
Kazunari Kamiko
Yokohama City University
10Publications
4H-index
33Citations
Publications 10
Newest
#1Masayo Kimura (YCU: Yokohama City University)H-Index: 2
#2Yoshinobu Kondo (YCU: Yokohama City University)H-Index: 6
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 8 authors...
Background: Low-carbohydrate diets have been shown to effectively improve the metabolic status of patients with type 2 diabetes mellitus. However, patients may find it challenging to maintain a strict low-carbohydrate diet. The objective of this study was to determine if a one-meal, low-carbohydrate diet is as effective in improving metabolic status as a conventional, energy-restricted diet among patients with type 2 diabetes mellitus. Methods: In this 12-week randomized controlled study, the pr...
3 CitationsSource
#1Kazutaka AokiH-Index: 15
#2Mieko NagakuraH-Index: 2
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 11 authors...
Background: Patients with type 2 diabetes mellitus often take multiple anti-diabetic drugs for a long period. Fixed dose combination (FDC) therapy is expected to improve drug adherence for patients with diabetes. The effect of switching from a loose dose combination (LDC) regimen to an FDC regimen at equivalent dosage on glycemic control has not been evaluated fully. Therefore, we investigated the effect of switching from LDC to FDC at equivalent dosage for 6 months on glycemic control in Japane...
2 CitationsSource
#1Hiroshi Kamiyama (YCU: Yokohama City University)H-Index: 6
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 7 authors...
Objective Switching from sulfonylureas to repaglinide in patients with type 2 diabetes improves glycemic control; however, the optimal dosage has not been fully evaluated. We designed to show that repaglinide was equivalent to sulfonylurea in Japanese patients with type 2 diabetes. We herein evaluated whether we could switch from sulfonylureas to repaglinide twice or thrice daily in Japanese adult patients who had been treated with anti-diabetic drugs, including sulfonylureas, and whose conditio...
2 CitationsSource
#1Kazunari Kamiko (YCU: Yokohama City University)H-Index: 4
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 5 authors...
Background: A fast eating speed is reportedly associated with obesity, fatty liver, and metabolic syndrome. As a comparison of postprandial glucose levels after eating quickly or slowly has not been previously reported for Japanese patients with type 2 diabetes, we evaluated the impact of the fast or slow ingestion of an enteral formula (liquid meal) on glucose metabolism. Methods: Ten Japanese patients with type 2 diabetes who had been hospitalized at our hospital were enrolled. All the subject...
1 CitationsSource
#1Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
#2Takahiro Ijima (YCU: Yokohama City University)H-Index: 1
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 5 authors...
Objective: The mechanism responsible for the lipid-lowering effect of dipeptidyl peptidase-4 (DPP-4) inhibitors remains unknown in humans. We evaluated the effect of anagliptin on serum lipid profiles, including cholesterol synthesis and absorption markers, in Japanese patients with type 2 diabetes.Methods: Thirty patients with type 2 diabetes (20 – 70 years old, low-density lipoprotein cholesterol (LDL-C) level over 120 mg/dl, and no history of treatment with antidiabetic or antihyperlipidemic ...
6 CitationsSource
#1Kazunari Kamiko (YCU: Yokohama City University)H-Index: 4
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 10 authors...
The half life (t1/2 ) of teneligliptin is 24.2 hours. Accordingly, we hypothesized that the administration of teneligliptin every other day might improve glycemic control. In this study, we evaluated the effectiveness of the administration of teneligliptin every other day in Japanese patients with type 2 diabetes. Fifty-one patients were randomly assigned to receive treatment with 20 mg of teneligliptin every day (Group A) or 20 mg of teneligliptin every other day (Group B) for 12 weeks. HbA1c, ...
1 CitationsSource
#1Hiroshi Kamiyama (YCU: Yokohama City University)H-Index: 6
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 7 authors...
ObjectivesTo compare the efficacy, safety and compliance of repaglinide, administered either two or three times daily, regarding glycaemic control in patients with type 2 diabetes mellitus.MethodsJapanese adults with type 2 diabetes mellitus, who had been treated without sulphonylureas or glinides for >3 months, were randomly assigned to two groups to receive either 0.25 mg repaglinide, oral, twice daily (group A) or 0.25 mg repaglinide, oral, three times daily (group B). Glycosylated haemoglobi...
1 CitationsSource
#1Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
#2Hiroshi Kamiyama (YCU: Yokohama City University)H-Index: 6
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 7 authors...
We previously reported that combination therapy with an α-glucosidase inhibitor (αGI) and a dipeptidyl peptidase-4 (DPP-4) inhibitor increased active glucagon-like peptide-1 (GLP-1) levels and decreased total glucose-dependent insulinotropic polypeptide (GIP) levels, compared with monotherapy, in non-diabetic men. However, the peptide YY (PYY), cholecystokinin (CCK), ghrelin, and obestatin levels in patients receiving a combination of αGIs and DPP-4 inhibitors have not been previously reported. ...
7 CitationsSource
#1Yoshinobu Kondo (YCU: Yokohama City University)H-Index: 6
#2Junko Hamai (YCU: Yokohama City University)H-Index: 1
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 13 authors...
Previous studies have shown that approximately 50% patients at risk of cardiovascular disease do not achieve lipid management goals. Thus, improvements dyslipidemia management are needed. We investigated the clinical choice and efficacy of second-line treatments for dyslipidemia in the Japanese clinical setting. Using a retrospective cohort design, we collected lipid profile data from patients who had been treated with hypolipidemic agents at a stable dosage for at least 12 weeks. These patients...
4 CitationsSource
#1Kiyomi Masuda (YCU: Yokohama City University)H-Index: 6
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 16 authors...
Objective: We investigated the effect of addition of alogliptin, while continuing the α-glucosidase inhibitor (αGI) administration at the same or reduced dose, or discontinuing the drug, on the glycemic control in type 2 diabetic patients showing inadequate response to αGI treatment. Research design and methods: A prospective, randomized, controlled, multicenter interventional study trial. Subjects were randomly assigned to treatment with alogliptin alone (Intake 0 group), or alogliptin in addit...
6 CitationsSource
1